180 Life Sciences EV / EBITDA
Was ist das EV / EBITDA von 180 Life Sciences?
EV / EBITDA von 180 Life Sciences Corp. ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit ev / ebitda ähnlich 180 Life Sciences
- Halo Collective hat EV / EBITDA von N/A
- Genetron Ltd hat EV / EBITDA von N/A
- Immunome hat EV / EBITDA von N/A
- CuriosityStream hat EV / EBITDA von N/A
- Cornerstone FS Plc hat EV / EBITDA von N/A
- Yuxing InfoTech Investment hat EV / EBITDA von N/A
- 180 Life Sciences hat EV / EBITDA von N/A
- Anglo African Oil & Gas Plc hat EV / EBITDA von N/A
- North Peak Resources hat EV / EBITDA von N/A
- Casablanca hat EV / EBITDA von N/A
- Predictive Oncology hat EV / EBITDA von N/A
- Theranexus SA hat EV / EBITDA von N/A
- 49 North Resources hat EV / EBITDA von N/A